MA49908A - Composés inhibant la protéine mcl-1 - Google Patents
Composés inhibant la protéine mcl-1Info
- Publication number
- MA49908A MA49908A MA049908A MA49908A MA49908A MA 49908 A MA49908 A MA 49908A MA 049908 A MA049908 A MA 049908A MA 49908 A MA49908 A MA 49908A MA 49908 A MA49908 A MA 49908A
- Authority
- MA
- Morocco
- Prior art keywords
- mcl
- protein inhibitors
- inhibitors
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762547589P | 2017-08-18 | 2017-08-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA49908A true MA49908A (fr) | 2021-04-28 |
Family
ID=63579748
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA049908A MA49908A (fr) | 2017-08-18 | 2018-08-17 | Composés inhibant la protéine mcl-1 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11364248B2 (fr) |
| EP (1) | EP3668878B1 (fr) |
| ES (1) | ES3036998T3 (fr) |
| MA (1) | MA49908A (fr) |
| WO (1) | WO2019036575A1 (fr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| MA50033A (fr) | 2017-08-29 | 2020-07-08 | Amgen Inc | Composés macrocycliques permettant d'inhiber la protéine mcl-1 |
| EP3762393B1 (fr) | 2018-03-05 | 2023-01-11 | Amgen Inc. | Pharmacophores d'acide alpha-hydroxy phénylacétique ou antagonistes de la protéine bio-isostère mcl-1 |
| KR102551319B1 (ko) | 2018-05-14 | 2023-07-05 | 길리애드 사이언시즈, 인코포레이티드 | Mcl-1 억제제 |
| TWI745836B (zh) * | 2019-01-18 | 2021-11-11 | 大陸商蘇州亞盛藥業有限公司 | 作為mcl-1抑製劑的大螺環醚 |
| KR20220034136A (ko) | 2019-07-09 | 2022-03-17 | 얀센 파마슈티카 엔.브이. | Mcl-1 억제제로서의 거대환식 스피로사이클 유도체 |
| TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
| AU2020391106B2 (en) | 2019-11-26 | 2024-03-21 | Gilead Sciences, Inc. | Processes and intermediates for preparing MCL1 inhibitors |
| AU2021288987A1 (en) * | 2020-06-10 | 2023-02-09 | Janssen Pharmaceutica Nv | Macrocyclic 2-amino-3-fluoro-but-3-enamides as inhibitors of MCL-1 |
| WO2022108984A1 (fr) | 2020-11-19 | 2022-05-27 | Gilead Sciences, Inc. | Procédés et intermédiaires pour la préparation d'inhibiteurs de mcl1 macrocycliques |
| MX2023007297A (es) | 2020-12-17 | 2023-07-04 | Janssen Pharmaceutica Nv | 3-fluoro-but-3-enamidas ramificadas macrociclicas como inhibidores de mcl-1. |
| ES3017082T3 (en) | 2021-04-26 | 2025-05-12 | Janssen Pharmaceutica Nv | Macrocyclic 2-allyltetrahydrofurans as inhibitors of mcl-1 |
| TWI910028B (zh) | 2021-06-11 | 2025-12-21 | 美商基利科學股份有限公司 | Mcl-1抑制劑與抗癌劑之組合 |
| US11931424B2 (en) | 2021-06-11 | 2024-03-19 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-body drug conjugates |
| KR20240107105A (ko) | 2021-11-16 | 2024-07-08 | 얀센 파마슈티카 엔브이 | Mcl-1의 억제제로서의 매크로사이클릭 2-아미노-부트-3-엔아미드 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5858784A (en) | 1991-12-17 | 1999-01-12 | The Regents Of The University Of California | Expression of cloned genes in the lung by aerosol- and liposome-based delivery |
| US6042820A (en) | 1996-12-20 | 2000-03-28 | Connaught Laboratories Limited | Biodegradable copolymer containing α-hydroxy acid and α-amino acid units |
| US6472375B1 (en) | 1998-04-16 | 2002-10-29 | John Wayne Cancer Institute | DNA vaccine and methods for its use |
| MY162157A (en) | 2007-04-16 | 2017-05-31 | Abbott Lab | Substituted indole mcl-1 inhibitors |
| CA2787784A1 (fr) | 2010-01-29 | 2011-08-04 | Dana-Farber Cancer Institute, Inc. | Petites molecules pour la modulation de mcl-1 et procedes de modulation de la mort cellulaire, la division cellulaire, la differenciation cellulaire et procedes de traitement de troubles |
| WO2013052943A2 (fr) | 2011-10-06 | 2013-04-11 | The Regents Of The University Of Michgian | Inhibiteurs à petite molécule de mcl-1 et leurs utilisations |
| ES2657649T3 (es) | 2012-03-29 | 2018-03-06 | The Regents Of The University Of Michigan | Inhibidores de Mcl-1 de molécula pequeña y sus usos |
| JO3474B1 (ar) | 2014-08-29 | 2020-07-05 | Amgen Inc | مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1 |
| US11306107B2 (en) * | 2016-02-25 | 2022-04-19 | Amgen Inc. | Compounds that inhibit MCL-1 protein |
| JP6453507B2 (ja) | 2017-03-30 | 2019-01-16 | アムジエン・インコーポレーテツド | Ｍｃｌ−１タンパク質を阻害する化合物 |
| MA50033A (fr) | 2017-08-29 | 2020-07-08 | Amgen Inc | Composés macrocycliques permettant d'inhiber la protéine mcl-1 |
| EP3762393B1 (fr) | 2018-03-05 | 2023-01-11 | Amgen Inc. | Pharmacophores d'acide alpha-hydroxy phénylacétique ou antagonistes de la protéine bio-isostère mcl-1 |
-
2018
- 2018-08-17 ES ES18769537T patent/ES3036998T3/es active Active
- 2018-08-17 EP EP18769537.4A patent/EP3668878B1/fr active Active
- 2018-08-17 MA MA049908A patent/MA49908A/fr unknown
- 2018-08-17 US US16/638,503 patent/US11364248B2/en active Active
- 2018-08-17 WO PCT/US2018/046859 patent/WO2019036575A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US11364248B2 (en) | 2022-06-21 |
| EP3668878B1 (fr) | 2025-05-21 |
| ES3036998T3 (en) | 2025-09-26 |
| WO2019036575A1 (fr) | 2019-02-21 |
| EP3668878A1 (fr) | 2020-06-24 |
| US20200360399A1 (en) | 2020-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL283639A (en) | Kif18a inhibitors | |
| MA49908A (fr) | Composés inhibant la protéine mcl-1 | |
| IL269196A (en) | Novel inhibitors | |
| PT3793565T (pt) | Inibidores mcl-1 | |
| FI3601297T3 (fi) | Mcl-1-proteiinia estäviä yhdisteitä | |
| EP3846674C0 (fr) | Spéculum vaginal | |
| EP3849534A4 (fr) | Polythérapies | |
| EP3555124C0 (fr) | Tcr nyeso | |
| DK3810587T3 (da) | Substituerede alkoxypyridinylindolsulfonamider | |
| DK3571192T3 (da) | Jak1-selektive inhibitorer | |
| EP3781060A4 (fr) | Cryosonde | |
| DK3737403T3 (da) | Modificerede adenovira | |
| DK3630744T3 (da) | Pyrazol-magl-inhibitorer | |
| EP3784463A4 (fr) | Fluorosulfones | |
| IL281514A (en) | O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors | |
| EP3810860C0 (fr) | Coupleur | |
| EP3797632A4 (fr) | Chaussure | |
| EP3600301A4 (fr) | Inhibiteurs de kdm4 | |
| MA46280A (fr) | Inhibiteurs de la dopamine-b-hydroxylase | |
| EP3792200A4 (fr) | Conteneur-citerne | |
| EP3745904C0 (fr) | Poignée de bâton | |
| EP3721129C0 (fr) | Cryosphère | |
| CL2018000262S1 (es) | Zapato | |
| EP3801525A4 (fr) | Inhibiteurs de la prolyl-arnt-synthétase | |
| EP3844177A4 (fr) | Polythérapies |